Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 161 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: interferon alfa-2a Clear all

Conditions: Hepatitis C Virus
Interventions: Sofosbuvir, Placebo to match sofosbuvir, PEG, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 22
States / cities: Montgomery, Alabama • Anaheim, California • Coronado, California + 17 more

Conditions: Hepatitis C
Interventions: peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 8
States / cities: San Francisco, California • Miami, Florida • Chicago, Illinois + 5 more

Conditions: Hepatitis C
Interventions: TMC435, Ribavirin (R), PegIFNα-2a (P), Placebo; Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 12
States / cities: Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 9 more

Conditions: Essential Thrombocythemia
Interventions: Bomedemstat, Anagrelide, Busulfan, Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b, Ruxolitinib; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 15
States / cities: Glendale, Arizona • Glendale, California • Stanford, California + 12 more

Conditions: Hepatitis C Virus
Interventions: Asunaprevir, Daclatasvir, Peg-interferon Alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 20
States / cities: Montgomery, Alabama • La Jolla, California • Los Angeles, California + 16 more

Conditions: Genotype 1 Chronic Hepatitis C
Interventions: GI-5005, Pegylated Interferon and Ribavirin; Drug
Lead sponsor: GlobeImmune; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 25
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 21 more

Conditions: Hepatitis C Infection, Thrombocytopenia
Interventions: romiplostim, ribavirin, placebo, PEG-interferon alfa-2a, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Squamous Cell Carcinoma of Skin, Carcinoma, Squamous Cell
Interventions: Pegylated Interferon alpha-2b, Capecitabine, 5-FU; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hepatitis C
Interventions: SOF, PEG, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: HIV Infections
Interventions: Pegylated interferon alfa-2a; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 3
States / cities: Sacramento, California • Chicago, Illinois • Durham, North Carolina

Conditions: Hepatitis C, Chronic
Interventions: peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 38
States / cities: Birmingham, Alabama • La Jolla, California • Lancaster, California + 32 more

Conditions: Hepatitis C, HIV Infections
Interventions: Double dose pegylated interferon with weight based Ribavirin, standard dose pegylated interferon alfa -2a and ribavirin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C
Interventions: CTS-1027, pegylated interferon, Ribavirin, Placebo; Drug
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 45
States / cities: Birmingham, Alabama • Coronado, California • La Jolla, California + 33 more

Conditions: Hepatitis C Virus Infection
Interventions: Daclatasvir, Asunaprevir, Pegylated interferon alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 20
States / cities: Montgomery, Alabama • La Jolla, California • Los Angeles, California + 17 more

Conditions: Hepatitis C
Interventions: Interferon-alpha; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 21 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Tucson, Arizona • Atlanta, Georgia

Conditions: Lymphoma
Interventions: filgrastim, recombinant interferon alfa, Etoposide, cyclophosphamide, doxorubicin hydrochloride, lamivudine, prednisone, vincristine sulfate, zidovudine; Biological · Drug
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years to 120 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 3
States / cities: Los Angeles, California • Miami, Florida • St Louis, Missouri

Conditions: Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Advanced Squamous Cell Carcinoma
Interventions: Cemiplimab-Rwlc, PEG-IFN alfa-2a; Drug
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Gastric Cancer
Interventions: filgrastim, recombinant interferon alfa, docetaxel, doxorubicin hydrochloride, fluorouracil, hydroxyurea; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 24
States / cities: Denver, Colorado • Chicago, Illinois • Peoria, Illinois + 18 more

Conditions: Lymphoma, T-Cell, Mycosis Fungoides, Hematologic Neoplasms
Interventions: Isotretinoin (Accutane), Interferon Alpha; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1990 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatitis C, Chronic
Interventions: Peginterferon alfa-2a [Pegasys], Peginterferon alfa-2b [PegIntron®]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 105
States / cities: Birmingham, Alabama • Dothan, Alabama • Fresno, California + 86 more

Conditions: Hepatitis C
Interventions: INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a, Ribavirin, Daclatasvir; Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Anaheim, California • La Jolla, California • San Francisco, California + 3 more

Conditions: High Risk Polycythemia Vera, High Risk Essential Thrombocythemia
Interventions: PEGASYS, Aspirin; Drug
Lead sponsor: Ronald Hoffman; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 16
States / cities: Scottsdale, Arizona • Palo Alto, California • Washington D.C., District of Columbia + 10 more

Conditions: Hepatitis C Virus Genotype-1
Interventions: TMC435, Pegylated interferon alpha-2a, Ribavirin; Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 10
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more

Conditions: Hepatitis B, Chronic
Interventions: JNJ-73763989, PegIFN-alpha-2a, Tenofovir disoproxil, Tenofovir alafenamide, JNJ-56136379; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Los Angeles, California • Pittsburgh, Pennsylvania • Seattle, Washington

Search by objective public record fields.

Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

Hepatitis C Antiviral Resistance in African-Americans

A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection

Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3

Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients

Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders

Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials

Inflammation, Stress & Social Behavior: Using Ecological Assessments & Model Systems to Enhance Relevance to Health Outcomes

Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma

Cemiplimab/Peg-Interferon-α in Advanced CSCC

Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer

Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies

PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection